Hemangioendothelioma
Symptoms, Doctors, Treatments, Advances & More

Hemangioendothelioma Overview

Save information for later
Sign Up

Learn About Hemangioendothelioma

What is the definition of Hemangioendothelioma?
The term Hemangioendothelioma describes several types of vascular neosplasms and includes both non-cancerous (benign) and cancerous (malignant) growths. The term has also been applied to those that show "borderline" behavior, intermediate between entirely benign hemangiomas and highly malignant angiosarcomas. Hemangioendotheliomas are caused by abnormal growth of blood vessel cells, although the exact underlying cause for the abnormal growth is unknown. They can also develop in an organ, such as the liver or lung. They usually grow slowly and can sometimes spread to other tissues in the body (metastasize). Examples of types of Hemangioendotheliomas include spindle cell hemangioma; papillary intralymphatic (Dabska tumor); retiform; kaposiform; epithelioid; pseudomyogenic (epithelioid sarcoma-like Hemangioendothelioma); and composite.
What are the alternative names for Hemangioendothelioma?
  • Hemangioendothelioma
Who are the top Hemangioendothelioma Local Doctors?
Elite in Hemangioendothelioma
Silvia Stacchiotti
Elite in Hemangioendothelioma
Silvia Stacchiotti
Milan, IT 

Silvia Stacchiotti practices practicing medicine in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Hemangioendothelioma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Hemangioendothelioma, and Synovectomy.

Elite in Hemangioendothelioma
Paolo G. Casali
Elite in Hemangioendothelioma
Paolo G. Casali
Milan, IT 

Paolo Casali practices practicing medicine in Milan, Italy. Mr. Casali is rated as an Elite expert by MediFind in the treatment of Hemangioendothelioma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Myxoid Liposarcoma, Solitary Fibrous Tumor, Pancreaticoduodenectomy, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hemangioendothelioma
Carlo Morosi
Elite in Hemangioendothelioma
Carlo Morosi
Milan, IT 

Carlo Morosi practices practicing medicine in Milan, Italy. Mr. Morosi is rated as an Elite expert by MediFind in the treatment of Hemangioendothelioma. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Hemangioendothelioma, Liposarcoma, Pancreaticoduodenectomy, and Liver Embolization.

View All Doctors
What are the latest Hemangioendothelioma Clinical Trials?
The Observational EURACAN Prospective Clinical Registry Dedicated to Epithelioid Hemangioendothelioma: the Protocol of an International and Collaborative Effort on an Ultra-rare Entity
The Observational EURACAN Prospective Clinical Registry Dedicated to Epithelioid Hemangioendothelioma: the Protocol of an International and Collaborative Effort on an Ultra-rare Entity
Enrollment Status: Recruiting
Publish Date: April 03, 2026

Summary: Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma, marked by distinctive molecular and pathological features and with a variable clinical behavior. Its natural history is still partially understood, reliable prognostic and predictive factors are lacking and many questions are still open on the optimal management. In the context of EURACAN, a prospective registry specifically dedicate...

Match to trials
Find the right clinical trials for you in under a minute
Get started
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Enrollment Status: Recruiting
Publish Date: March 03, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-s...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center